Research Reports
Arch Pharmalabs Unlisted Shares
Arch Pharmalabs company logo

Arch Pharmalabs Share Price

PHYSICAL
PRIVATE LIMITED

Price Chart

1W
1M
1Y
MAX
High

₹135

Low

₹85

Return

-16.67%

Arch Pharmalabs Essentials

As of March 30, 2026, Arch Pharmalabs, Unlisted Shares are trading at ₹110.00 per share and face value is ₹10.00/share, with a 52-week high of ₹110.00 and 52-week low of ₹110.00. The minimun lot size is 1850 shares, and the shares are traded on NSDL and CDSL.
ISIN
info icon
INE182F01017
Face Value
info icon
10
Total Shares
info icon
15,19,23,076
Market Cap
info icon
1,671.15 Cr
Profit After Tax
info icon
124.95 Cr
Total Revenue
info icon
1,340.98 Cr
P/E
info icon
13.72
Sector
info icon
Health Care
Sub-sector
info icon
Pharmaceuticals
Category
info icon
Delisted
Cashflow - Operations
info icon
42.49 Cr

About Arch Pharmalabs

  • Arch Pharmalabs established on 2nd April 1993 is a pharmaceutical company aligned across two business verticals viz. Products and Services. Their Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. They have evolved their business and have, over the years, extended from manufacturing APIs and Intermediates to add CRAMS to their offerings, which has significant potential for the growth of our business.
  • The company operates three state-of-the-art facilities for API manufacturing: the Vitalife Site in Gurgaon, the Oncology Site in Tarapur, and the Dombivli Site in New Mumbai. Additionally, it has four facilities dedicated to intermediate manufacturing: the Merven Site and Watsol Site in Hyderabad, and the Badlapur Site and Taloja Site in Mumbai.
  • Arch Pharmalabs have a diversified portfolio product mix of more than 120 products (over 65 APIs and over 55 Intermediates) across various therapeutic segments including side chains of semi–Synthetic Isoxazole Penicillins under Antibiotics, Lipid Lowering Agents, Oncology, Anti-Platelet Agents, Anti-Asthmatic, Anti-Retroviral, Decongestant, Anti-Herpes, Anti-Malarial, NSAIDs, Anti-Anginal segments.

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Arch Pharmalabs Media

News
Articles
Videos
NCLT rejects JM Financial Asset Reconstruction's plea in Arch Pharmalabs case
NCLT rejects JM Financial Asset Reconstruction's plea in Arch Pharmalabs case
22 May 2024
The Economic Times
FinMin reviews bankruptcy proceedings of Arch Pharma Labs, Among other high-profile cases.
FinMin reviews bankruptcy proceedings of Arch Pharma Labs, Among other high-profile cases.
05 May 2024
Money control
Mitsui & Co buys additional 25% stake in Arch Pharmalabs for Rs 372 crore
Mitsui & Co buys additional 25% stake in Arch Pharmalabs for Rs 372 crore
16 Sep 2012
economictimes

Arch Pharmalabs

₹ 110

cartIcon